Amount Raised
$11 Million
BostonDescription
EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible note round of financing (“the Financing”) comprised of Vectura Group plc, the Cystic Fibrosis Foundation and Sanford Biosciences LLC.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech